Table 1

Secondary and exploratory objectives and outcomes

Key secondary objectivesKey secondary outcome measures
To compare the effect of video consultations, relative to control, on HbA1C from baseline to week 52HbA1C % (time frame: 0, 52 weeks)
To compare the effect of video consultations, relative to control, on changes in quality of life from baseline to week 52ADDQoL19 (time frame: 0, 52 weeks)
To compare the effect of video consultations, relative to control, on changes in treatment satisfaction, at week 52DTSQc (time frame: 52 weeks)
To compare the effect of video consultations, relative to control, on treatment satisfaction from baseline to week 52DTSQs (time frame: 0, 52 weeks)
To compare the effect of video consultations, relative to control, on changes in TbR level 2 from baseline to week 52Percentage of TbR level 2 (<3.0 mmol/L) (time frame: 0, 52 weeks)
To compare the effect of video consultations, relative to control, on changes in TbR level 1 from baseline to week 52,Percentage of TbR level 1 (3.0–3.8 mmol/L) (time frame: 0, 52 weeks)
To compare the effect of video consultations, relative to control, on changes in TaR level 2 from baseline to week 52,Percentage of TaR level 2 (>13.9 mmol/L) (time frame: 0, 52 weeks)
To compare the effect of video consultations, relative to control, on changes in TaR level 1 from baseline to week 52,Percentage of TaR level 1 (10.1–13.9 mmol/L) (time frame: 0, 52 weeks)
To compare the effect of video consultations, relative to control, on changes in glycaemic variability (%GCV) range from baseline to week 52Glycaemic variability (%GCV) (time frame: 0, 52 weeks)
Other—explorative—objectivesOther—explorative—outcomes
To compare the direct and indirect cost of video consultations, relative to control during the trial.Direct and indirect cost (time frame: 0–52 weeks)
To compare the effect of video consultations, relative to control, on changes in quality of life, at week 52EQ-5D-5L (time frame: 0, 52 weeks)
To explore patients’ (in the intervention group) and providers’ experience after participation in the trial.Semistructured interviews with intervention group and healthcare professionals (time frame: after completion of study)
  • ADDQoL19, Audit of Diabetes Dependent Quality of Life; DTSQc, Diabetes Treatment Satisfaction Questionnaire (status); DTSQc, Diabetes Treatment Satisfaction Questionnaire (change); EQ-5D-5L, The EuroQol Five Dimensions; HbA1C, glycated hemoglobin; TaR, time above range; TbR, time below range.